The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

By J. A. Lemos, D. A. Morrow, J. Bentley, T. Omland, M. Sabatine, C. Mccabe, C. Hall, C. Cannon, E. Braunwald. New England Journal of Medicine, 2001

1,273 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/80c117ffe5f67a601620de837bb068d19ad1dcf0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Robert M. Califf
2. Eric J. Topol
3. Hani Jneid
4. Allan S. Jaffe

Citations in the corpus

• N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy (2003, background): “4% (3) in the lowest decile ( 98 ng/L) and 27.”
• Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2002, background): “Elevated levels of brain natriuretic peptide (BNP) and interleukin-6 (IL-6) on admission are strongly related to mortality both in the short- and long-term([97]).”
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Use of selected newer biomarkers, especially B-type natriuretic peptide, may be reasonable to provide additional prognostic information (87, 88, 167-171).”